Aurobindo Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 19.62% fall in its net profit at Rs 644.80 crore for the quarter under review as compared to Rs 802.16 crore for the same quarter in the previous year. However, total income of the company increased by 16.21% at Rs 3,835.61 crore for Q4FY23 as compared to Rs 3,300.54 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 12.19% fall in its net profit at Rs 505.91 crore for fourth quarter ended March 31, 2023 as compared to Rs 576.14 crore for the same quarter in the previous year. However, total income of the company increased by 12.80% at Rs 6,607.87 crore for Q4FY23 as compared to Rs 5,858.25 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 15.42% fall in its net profit at Rs 1,230.41 crore as compared to Rs 1,454.71 crore for the previous year. However, total income of the company increased by 10.60% at Rs 13,226.04 crore for year under review as compared to Rs 11,958.13 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 27.18% fall in its net profit at Rs 1,927.65 crore as compared to Rs 2,647.11 crore for the previous year. However, total income of the company increased by 5.76% at Rs 25,145.97 crore for year under review as compared to Rs 23,775.84 crore for year ended March 31, 2022.
